CYP 2.33% 21.0¢ cynata therapeutics limited

Ann: Cynata to Acquire IP from Tekcyte, page-3

  1. 857 Posts.
    lightbulb Created with Sketch. 341
    A great result. I was expecting the acquisition costs may have been 10-20 times greater, thereby if a license was signed then most of the potential upfront payment would have been consumed by these costs.

    $230k is a drop in the ocean compared to what we might get upfront from a partnership deal with Big Pharma.
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.